In particular, several biologics have been approved during the last five years, targeting tumor necrosis factor-alpha (TNF-α) or interleukin (IL)-23, IL-12/23, or IL-17, which have been established as the pivotal cytokines in the pathogenesis of psoriasis [5,6,7]. The gene discussed is TNF; the disease is psoriasis.